News Updates[COVID Positive Cases Detected In HC] Orissa HC To Remain Closed on September 21 And 22 For ‘Extensive Sanitization’ [Read Order] Sparsh Upadhyay20 Sep 2020 11:34 PMShare This – xThe High Court of Orissa has notified (On 20th September) that in view of detection of COVID-19 Positive cases in some of the sections of the High Court, the High Court and its Offices shall remain closed on 21-September and 22-September for the purpose of “extensive sanitization” of the entire premises of the High Court Building.It has also been notified that matters in the cause list…Your free access to Live Law has expiredTo read the article, get a premium account.Your Subscription Supports Independent JournalismSubscription starts from ₹ 599+GST (For 6 Months)View PlansPremium account gives you:Unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments.Reading experience of Ad Free Version, Petition Copies, Judgement/Order Copies.Subscribe NowAlready a subscriber?LoginThe High Court of Orissa has notified (On 20th September) that in view of detection of COVID-19 Positive cases in some of the sections of the High Court, the High Court and its Offices shall remain closed on 21-September and 22-September for the purpose of “extensive sanitization” of the entire premises of the High Court Building.It has also been notified that matters in the cause list of 21.09.2020 will be taken up on 23.09.2020.The bail applications from the Reserved Lists published for 22.09.2020, 23.09.2020, 24.09.2020 and 25.09.2020 will be taken up on 24.09.2020, 25.09.2020, 28.09.2020 and 29.09.2020 respectively.It may be noted that a number of courts had to limit/suspend the regular functioning owing to positive cases being detected on their campuses.Recently, the High Court of Manipur had suspended the normal functioning/sitting of the Court till 21st September in view of the detection of a COVID case within the High Court premises.The Registrar of the High Court had mentioned in the Notification issued on Thursday (17th September) that no cause list will be published for the said period (till September 21st).The Manipur High Court Bar Association on Thursday (17th September) had requested the Chief Justice of Manipur High Court to adjourn Court proceedings for at least one week.Recently, the Gujarat High Court had decided to remain closed from September 12, 2020 till September 15, 2020, after 12 Court employees tested COVID positive on Wednesday (09th September).Also, in view of the significant increase in the number of positive patients of Corona Virus, High Court of Madhya Pradesh at Principal Seat Jabalpur Hon’ble the Chief Justice had ordered that the Judicial and Administrative functioning of the High Court of Madhya Pradesh at Principal Seat Jabalpur and its Registry shall remain closed for the period of 16-09-2020 to 20-09-2020 ( 16 & 18/09/2020 working days, 19/09/2020 – 2nd Saturday and 17 & 20/09/2020 public holidays) to ensure the effective and proper sanitization, to break the chain of COVID-19 in the Court premises and to stop physical and E-Filing from 05.00 PM of 15-09-2020 till 10.00 AM of 21-09-2020.Click Here To Download Order[Read Order] Subscribe to LiveLaw, enjoy Ad free version and other unlimited features, just INR 599 Click here to Subscribe. All payment options available.loading….Next Story
Patients with severe TB disease when they started treatment had worse outcomes than patients with less severe disease. Sixty-eight percent of people with severe disease had early favorable responses to the new regimen, compared to 89 percent without severe disease. Among patients with HIV coinfection, early outcomes on the new regimens were favorable in 73 percent, compared to 84 percent in those without HIV.The results are based on an analysis of early treatment results from more than 1,000 MDR-TB patients who were enrolled in the study between April 2015 and March 2018. The study examines outcomes after six months in a treatment that lasts 15 months or longer. Long-term effectiveness will be measured at the end of treatment and during follow-up.For this study, the researchers counted how many of those patients, within the first six months of treatment with regimens containing bedaquiline, delamanid, or both, experienced culture conversion, a state in which the bacteria that cause TB can no longer be found on a sample. Previous studies have shown this to be a strong predictor of successful treatment outcomes.Confirmation with end-of-treatment outcomes will be important and more work needs to be done to ensure successful treatment in these populations, the researchers said.“The early results from these studies offer convincing evidence that these new regimens offer a very promising alternative to the historical regimens that achieve approximately 60 percent success at end of treatment, and to other new treatments that are becoming available,” said Mitnick, who is a senior researcher at Partners In Health and co-principal investigator of the clinical trials being conducted by endTB.“We’re eager to follow these patients as they progress through treatment in order to verify the effectiveness of these new regimens,” she added.Complex challengesObservational research makes so many important contributions to improving treatment outcomes for complex illnesses in complicated populations that it is critical to continue research efforts past the stage of clinical trials in illnesses like tuberculosis, the researchers said.While tuberculosis has nearly disappeared in wealthier populations, it remains a critical threat in communities with fewer resources. A big part of the challenge of treating MDR-TB is finding regimens that will work in low-resource settings with complex populations that often include great diversity and many people who might be undernourished or sick with other illnesses.The partnership is also studying the safety of the new regimens. Preliminary results suggest that side effects from the new regimen may be much less severe than those seen with the historical treatment, which has been known to cause deafness and psychosis.“TB is well-controlled where control is easy,” Mitnick said. “We need to find better ways to treat it where it’s difficult.”The global reach of endTB has now provided clinicians with invaluable hands-on experience with bedaquiline and delamanid and helped change country guidelines, getting the new drugs registered for use in more than half of the17 endTB countries, the researchers said. The endTB observational study has contrinuted to changing global guidelines, including new recommendations for concomitant use of bedaquiline and delamanid and extended use of each drug.Moving forwardThe endTB partnership is using the same model for promoting innovation to prepare for what researchers hope will be the next change on the horizon in care for MDR-TB: all-oral, shortened regimens, which are being studied in the current phase of endTB’s clinical trial. While the implementation program continues to roll out and reaches new patients, the endTB trial has enrolled 465 patients with MDR-TB in new all-oral regimens that could transform care for MDR-TB.The all-oral regimens used in the endTB observational study and the all-oral, shortened regimens studied in the trials would be particularly helpful during international health crises like the coronavirus pandemic, the researchers noted. These all-oral regimens are much easier to deliver in routine times and especially so in times of extreme crisis that burden health systems.“If the ongoing trials demonstrate reduced toxicity of the all-oral, shortened regimens, this is another huge benefit for their delivery in good times and bad,” Mitnick said.The project also transformed the landscape for TB trials by running in six countries (Georgia, Kazakhstan, Lesotho, Pakistan, Peru, South Africa) on four continents. This is the first time a clinical trial has taken place in some of these sites, the researchers said.“In global health we see many vicious cycles, where poverty and lack of access to care combine to make diseases worse,” Franke said. “On the other hand, bringing care delivery, training and research together the way we are in the endTB project can be a kind of virtuous cycle, where each turn of the wheel brings better care, improved health and greater well-being.”The endTB project is funded by Unitaid. International epidemic expertise to help Massachusetts respond to COVID-19 New blood monitoring could be used to help people infected with tuberculosis New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.The results, based on observational data from a diverse cohort of patients in 17 countries, underscore the need for expanded access to the recently developed TB medicines bedaquiline and delamanid. By contrast, the historical standard of care, still in use in much of the world, has approximately 60 percent treatment efficacy globally.The study was published July 24 in the American Journal of Respiratory and Critical Care Medicine.“This is important evidence that these new regimens will work well for the true population suffering from this disease,” said lead study author Molly Franke, associate professor of global health and social medicine in the Blavatnik Institute at Harvard Medical School.Global collaborationThe research was conducted as part of endTB, an international partnership with leaders from HMS, Partners In Health, Médecins Sans Frontières, Interactive Research & Development, the Institute of Tropical Medicine in Antwerp, and Epicentre.“Our findings underscore the need for urgent expanded access to these drugs,” said Carole Mitnick, associate professor of global health and social medicine in the Blavatnik Institute at HMS and a co-author of the study. While recent announcements of a price reduction for bedaquiline and an expected reduction for delamanid are welcome, the researchers said, more must be done to improve treatment guidelines worldwide and to scale up treatment with these new regimens.The need for better treatments for MDR-TB is dire. The WHO estimates that there are nearly 500,000 new cases of MDR-TB per year and that nearly 200,000 people die of the disease each year . In 2018, only one out of three patients were given an effective treatment, and only half of these were cured.New hopeIn the early 2010s, regulatory agencies approved the first new TB drugs in 50 years, bedaquiline and delamanid, offering hope for more effective and less toxic MDR-TB treatment. With the historical standard of care and some newer regimens, certain subgroups of patients, including those with HIV or hepatitis C or diabetes experience worse treatment outcomes than patients without these conditions. In addition, these conditions preclude patients from participating in clinical trials for these drugs.It’s important to examine whether these subgroups experience any benefit from the new regimens that might be observed in healthier study participants, the researchers said. They noted that only a large cohort study has the statistical power to explore these differences.The endTB study showed that for the new regimens, early treatment response was similar for patients without serious comorbidities or other complicating factors and for those with diabetes, hepatitis C and severe drug resistance. Related Community contact tracing A timely triage test for TB
Will Blozan climbs hemlock trees for a living. It might be the perfect job, if he didn’t have to worry about those trees being gone in the next five years. Blozan is the subject of a new documentary, The Vanishing Hemlock: A Race Against Time. It follows the arborist’s quest to save the last remaining stands of old growth hemlock trees in the Southern woods. Hemlocks—some approaching 500 years old—are literally having the life sucked out of them by the woolly adelgid, a non-native insect introduced from Asia. Since 2002, it has been ravaging hemlock populations in the South, especially in Great Smoky Mountains National Park. For the past five years Blozan has dedicated his life to researching and treating hemlock trees in the Southern Appalachians. One of his biggest efforts, the Tsuga Search Project, is measuring and documenting the world’s tallest Eastern Hemlocks before they are exctinct. He’s a lone eco-warrior fighting a seemingly impossible battle, due to inaction by the government and continued public apathy. Although he admits saving hemlocks is a personal crusade for a species he loves, it is also a quest for ecological preservation, something everyone needs to consider.——————–BRO: When did the hemlock personally become so important to you?WB: When I worked for the National Park Service in 1993, I was hired specifically to survey and map these trees. Being out there in the backcountry with these ancient trees, the largest evergreen conifer in the Eastern U.S., I was able to develop a certain respect.BRO: Your company has been contracted by the government to treat trees in Great Smoky Mountains National Park. What’s your assessment of the trees in this daily work?WB: It depends a lot on the vigor of the trees. I can say that just about 100 percent of the hemlocks in the park have been infested. I’ve seen a lot of mortality this year. I have been treating adelgid since it arrived in 2002, and the trees that I reached right away are doing well. But some that weren’t treated have already died. It only takes five years. The trees that I am treating right now are heavily infested, and a lot of them have died this year, because of the drought. It’s a combination of stresses.BRO: Now that you are working with the government, can this be reversed?WB: It’s four years too late. They’ve known about this since 2002 and didn’t start treating until 2005. I don’t know why the Park Service waited so long to get going. They are not putting enough into this. The national park was established to preserve the superlative forest. But they recently received $18 million to repair a one-way dirt road that nobody really uses. That money should be going to save the hemlocks, which are the whole reason the park was established. Some of these forests could have been saved for a couple thousand dollars. The priorities are way off. It’s unfortunate that this lesson had to be learned in the national park, which is the epicenter of these trees.BRO: You treat trees with Imidacloprid, which is a controversial pesticide. Why do you use this instead of biological controls like predatory beetles?WB: Research has shown that as long as there’s organic material in the soil, the molecule in the pesticide binds so tightly that it can’t move and leach out of the soil. It’s been proven in a laboratory and a new field study that’s about to get published. The predator beetle has been released extensively, and it just can’t work. It’s true that it eats adelgid, but it physically cannot solve the problem because of sheer numbers. Their numbers cannot match the reproductive numbers of the adelgid. One tree can produce tens of billions of adelgidBRO: Public apathy is another reason hemlocks continue to perish. Why should our readers care?WB: To me the hemlock forests represent a link to our past that’s viable in its own right. I realize not everyone appreciates trees like I do, but this is a species that has an impact on people because of its size, shape, and character. Every time I take people into hemlock forests they get really quiet and touch the trees. They have an impact and create a deep connection to the earth.From an ecological standpoint, there are a number of species that are dependent on hemlocks. Water quality is a big concern. We could have higher flash flood events, and highly acidic water. Hemlocks are wet and spongy, so they moderate high rainfall by absorbing water, and basically prevent flooding. Wildfire could also be a big problem, because we’ll have all of this dead dry wood lying around. Some of these forests haven’t burned in a millennium. With the open sunlight being able to hit the forest floor without shade, dry weather would make these areas a tinderbox.BRO: Where do we go from here, now that the problem is so widespread?WB: There are many places out there that still have a lot of healthy hemlock growth. I don’t see any need to choose to let them die. I have no expectations of saving every tree. But there are some super high quality sites, like Fall Creek Falls State Park in Tennessee, which do not have adelgid infestations at this point. We need to encourage people to save these forests, while they still can, and maintain them for the future.There is a false idea out there that preserving hemlocks is unaffordable, mainly because private companies are charging too much, riding the wave of alarm. The chemical is cheap, and the application is easy. I don’t understand how we as a human species can let another species go extinct, when there’s a reasonable, affordable option.BRO: What’s the goal for you in being the subject of this film?WB: I want my kids to be able to visit a healthy hemlock forest. My goal is to alert people to how serious this pest is and how quickly it kills. But also they need to realize how easy it is to save these forests. Public landowners need to do it. It’s a black and white situation. If this was happening in Redwoods National Park, I guarantee there would be a huge effort to make a difference.
Share Betsson outrides pandemic challenges as regulatory dramas loom July 21, 2020 Related Articles Submit Share GiG lauds its ‘B2B makeover’ delivering Q2 growth August 11, 2020 StumbleUpon LeoVegas hits back at Swedish regulations despite Q2 successes August 13, 2020 Issuing its first trading statement as a Nasdaq Stockholm-listed enterprise, Gaming Innovation Group (GiG) details a tough opening to 2019 trading, as the company undertakes Swedish market adjustments.Updating investors, GiG records a 13% group revenue decline to €32 million (Q12018: €37m), attributed to anticipated Swedish market costs following the re-regulation of the market.Swedish adjustments impacted GIG’s revenue segments for both B2B €14.2 million (Q12018: €15.3m) and B2C €20.2 million (Q12018: €25.4m) segments.Adjusting to new Swedish conditions, GiG governance details that the company ‘tightened its cost control’, reducing its period cost of sales and marketing expenditures.Despite its revenue slowdown, GiG maintained a positive EBITDA of €4.1 million (Q12018: €4.3m) in-line with corporate expectations.Robin Reed, GiG CEO, commented: “The Company delivered an EBITDA of €4.1m in Q1 and the key highlight was all-time high revenues and EBITDA in our media business. It is a performance I am reasonably satisfied with in light of the loss of a major B2B customer which we announced in Q4-18, and the new regulation in Sweden which is impacting both our B2C and B2B revenues. We had anticipated this and managed the impact by careful cost control.“The business is robust with cash flow from operating activities of €2.6m. GiG has become better and more competitive as the Company matures. Our leadership has never been stronger, our processes are more robust, and our strategic understanding and intent has evolved. I am looking forward with confidence to the growth opportunities for the rest of the year.”
Matthew Stafford injury update: Lions QB expected to play vs. Chiefs Bears’ Matt Nagy praises Khalil Mack: He’s ‘on another level right now’ Melvin Gordon activated by Chargers, reportedly will have limited role vs. Dolphins Saquon Barkley is optimistic he will return from his injury sooner than later. The Giants running back, who is recovering from a high ankle sprain, has told people he can beat his four- to six-week timetable for recovery, according to NFL Network, which cited unidentified sources. The report added, however, that the Giants’ training staff will make sure he’s cautious in making his return. Per @KimJonesSports, #Giants RB Saquon Barkley is already telling people he can beat the timetable for recovery from a high-ankle sprain, while the team training staff will make sure he’s cautious enough.— Ian Rapoport (@RapSheet) September 29, 2019Barkley injured his ankle in the second quarter of Week 3’s win over the Buccaneers and had to be helped to the locker room. He came back to the sideline using crutches and wearing a walking boot.Coach Pat Shurmur said earlier this week that New York doesn’t plan on placing the star on injured reserve. Related News “At this point, no. … I want to be clear, [the plan] doesn’t involve putting Saquon on IR,” Shurmur told reporters Thursday. “Rehab him and get him ready to go. See how that plays out.”Shurmur’s comments come after Barkley visited specialist Dr. Robert Anderson in Green Bay, who reportedly told the running back that he won’t need surgery, according to NFL Network. TightRope surgery was an option to help stabilize the ankle, which is a procedure Alabama quarterback Tua Tagovailoa had last year on his high ankle sprain.Barkley, selected with the second overall pick in the 2018 draft, had rushed for team-high 227 yards, second in the NFL, and had one rushing touchdown in two games entering Week 3. He had eight carries for 10 yards and four receptions for 27 yards before leaving Sunday. Last season, he led the league with 2,028 yards from scrimmage as a rookie and also scored 15 total touchdowns to earn 2018 NFL Rookie of the Year honors.Wayne Gallman, who had five carries for 13 yards in Sunday’s game and has only seven carries for 30 this season, is expected to carry the backfield workload in Barkley’s absence.The Giants (1-2) are will host the Redskins (0-3) at 1 p.m. ET Sunday.